Hubei Biocause Pharmaceutical Co., Ltd.

000627

CNE000000F48

Life & Health Insurance

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-26 pm EDT			5-day change	1st Jan Change
2.27 ^CNY	-0.87%		-6.58%	-20.07%

Apr. 29	Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 15	Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 30 May 2023

May 22, 2023 at 03:31 pm EDT

Hubei Biocause Pharmaceutical Co., Ltd. approved final cash dividend per 10 A shares (tax included) of CNY 1.10000000 for the year 2022 at its AGM held on 19 May 2023. Record date is 29 May 2023; Ex-date is 30 May 2023; Payment date is 30 May 2023. Net cash dividend/10 shares after tax: CNY 0.99000000 (CNY 1.10000000 - CNY 0.11000000).

Latest news about Hubei Biocause Pharmaceutical Co., Ltd.

Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023	Jan. 15	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Hubei Biocause Pharmaceutical Co., Ltd. agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million.	23-09-21	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Biocause Pharma Unit Logs 31 Million Yuan Insurance Premium Income in January-July Period	23-08-14	MT
Biocause Pharma Unit Generates 24 Billion Yuan Premium Income in January-May Period	23-06-12	MT
Biocause Pharma’s Life Insurance Unit Generates 22 Billion Yuan in January-April Premium Income	23-05-16	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Hubei Biocause Pharmaceutical Gets Regulatory Nod for Ibuprofen; Shares Down 5%	22-12-30	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Biocause Heilen Pharma to Unlock 1.21% Restricted Stake	22-06-19	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI
Hubei Biocause’s Pharmaceutical Ingredients Unit Surges 64% in Shenzhen Debut	21-12-21	MT
Hubei Biocause’s Pharmaceutical Ingredients Unit Targets $243 Million in Shenzhen IPO	21-12-09	MT
Hubei Biocause’s Pharmaceutical Ingredients Unit Launches Shenzhen IPO	21-12-02	MT
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-30	CI
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-29	CI
Hubei Biocause Pharmaceutical Co., Ltd. Announces Board Appointments	20-06-15	CI
Hubei Biocause Pharmaceutical Co., Ltd. cancelled the acquisition of remaining 49% stake in Guohua Life Insurance Co., Ltd. from Hainan Kaiyi Industrial Co., Ltd., Shanghai Boyonglun Technology Co., Ltd., Ningbo Hanshengxin Investment Co., Ltd., Hubei Hongtai State-owned Capital Investment Operation Group Co., Ltd., Wuhan Real Estate Development & Investment Group Co., Ltd. and Wuhan Jiang’an State-owned Asset Management Co., Ltd.	20-05-25	CI
Hubei Biocause Pharmaceutical Co., Ltd. cancelled the transaction announced on August 26, 2019	20-05-25	CI

Chart Hubei Biocause Pharmaceutical Co., Ltd.

Duration

Period

Chart Hubei Biocause Pharmaceutical Co., Ltd.

More charts

Company Profile

Hubei Biocause Pharmaceutical Co.,Ltd. is a China-based company principally engaged in insurance business, such as life insurance, health insurance and casualty insurance. The Company is also involved in pharmaceutical business and chemical business. The Companyâs products include polypropylene and Ibuprofen. The Company distributes its products in domestic market and to overseas markets, with Central China and South China as its main markets.

Sector

Life & Health Insurance

Calendar

2024-09-01 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Life & Health Insurance

	1st Jan change	Capi.
HUBEI BIOCAUSE PHARMACEUTICAL CO., LTD.	-20.07%	1.56B
AXA	+14.24%	80.24B
METLIFE, INC.	+9.69%	51.58B
AFLAC INCORPORATED	+6.29%	49.83B
MANULIFE FINANCIAL CORPORATION	+24.73%	47.73B
PRUDENTIAL FINANCIAL, INC.	+15.09%	42.86B
GENERALI	+23.16%	39.39B
SUN LIFE FINANCIAL INC.	+2.15%	29.67B
PRUDENTIAL PLC	-13.68%	26.75B
CATHAY FINANCIAL HOLDING CO., LTD.	+21.53%	24.99B

Other Life & Health Insurance